This is a demo store. No orders will be fulfilled.

Retifanlimab (anti-PD-1), 程序性细胞死亡 1 (CD279) 抗体

    应用:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • 宿主种属: 人(Human)
  • 种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
  • 亚型: Human IgG4SP
  • 偶联: Unconjugated
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
Ab175644-100μg
100μg 现货 Stock Image
Ab175644-1mg
1mg 现货 Stock Image
Ab175644-5mg
5mg 现货 Stock Image
Ab175644-10mg
10mg 期货 Stock Image

基本信息

产品名称 Retifanlimab (anti-PD-1), 程序性细胞死亡 1 (CD279) 抗体
别名 瑞弗利单抗 | 雷替凡利单抗(抗-PD-1)
英文别名 CD279 antibody | CD279 antigen antibody | hPD 1 antibody | hPD l antibody | hPD-1 antibody | hSLE1 antibody | PD 1 antibody | PD-1 antibody | PD1 antibody | PDCD 1 antibody | PDCD1 antibody | PDCD1_HUMAN antibody | Programmed cell death 1 antibody | Progr
规格或纯度 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属 人(Human)
特异性 PDCD1
种属反应性 人(Human),食蟹猴(Cynomolgus monkey)
偶联 Unconjugated
作用类型 拮抗剂
作用机制 程序性细胞死亡 1 (CD279) 抗体

产品属性

克隆类型 重组抗体
Format Whole IgG
亚型 Human IgG4SP
轻链亚型 kappa
SDS-PAGE 25.5 kDa (Light Chain) & 50.1kDa (Heavy Chain), under reducing conditions; 179.1 kDa, under non-reducing conditions.
纯化方法 Protein A purified
纯度 >95%
物理外观 Liquid
储存缓冲液 Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 见COA
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息 2079108-44-2
分子类型 抗体

关联靶点(人)

PDCD1 Tclin 程序性细胞死亡蛋白 1(Programmed cell death protein 1) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
PDCD1 Tclin Programmed cell death protein 1 (14 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

图片

Retifanlimab (anti-PD-1) (Ab175644) - Flow Cytometry
Flow Cytometry analysis of 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated MOLT-4 cells (24h) labelling PD-1 (red) with Retifanlimab (anti-PD-1) (Ab175644). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.


Retifanlimab (anti-PD-1) (Ab175644) - ELISA
Immobilized hu-PD-1 at 2 μg/mL can bind Retifanlimab (anti-PD-1) (Ab175644) with the EC₅₀ of 55.56 ng/mL.

Retifanlimab (anti-PD-1) (Ab175644) - SEC
The purity of Retifanlimab (anti-PD-1) (Ab175644) is more than 95% verified by HPLC.

Retifanlimab (anti-PD-1) (Ab175644) - ELISA
Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Retifanlimab (anti-PD-1) (Ab175644) with the EC50 of 11.39 ng/mL.

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到3个结果

批号(Lot Number) 证书类型 货号
ZJ24F0303705 分析证书 Ab175644
ZJ24F0303704 分析证书 Ab175644
ZJ24F0303703 分析证书 Ab175644

可替换产品

引用文献

1. Farias JPF, Rangel da Silva MHC, Jácome AA.  (2021)  Emerging and Experimental Agents for Anal Cancer: What is New?.  J Exp Pharmacol,  13  (433-440).  [PMID:33859504]
2. Kline J, Gajewski TF.  (2010)  Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer..  Curr Opin Investig Drugs,  11  (12): (1354-9).  [PMID:21154117]
3. Hall RD, Gray JE, Chiappori AA.  (2013)  Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer..  Cancer Control,  20  (1): (22-31).  [PMID:23302904]
4. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al..  (2017)  Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice..  Mol Cancer Ther,  16  (5): (861-870).  [PMID:28265006]
5. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips.  (1997-10-23)  The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors..  Gene,  197  ((1-2)): (177-187).  [PMID:9332365]
6. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T..  (1994)  Structure and chromosomal localization of the human PD-1 gene (PDCD1)..  Genomics,  [PMID:7851902]
7. Prokunina, Ludmila L and 23 more authors..  (2002)  A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans..  Nature genetics,  [PMID:12402038]
8. Topalian, Suzanne L SL and 29 more authors..  (2012)  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer..  The New England journal of medicine,  (28): [PMID:22658127]
9. Robert, Caroline C and 27 more authors..  (2015)  Nivolumab in previously untreated melanoma without BRAF mutation..  The New England journal of medicine,  (22): [PMID:25399552]
10. McDermott, J J and Jimeno, A A..  (2015)  Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer..  Drugs of today (Barcelona, Spain : 1998),  [PMID:25685857]
11. Na, Zhenkun and 6 more authors..  (2017)  Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab..  Cell research,  [PMID:27325296]
12. Pascolutti, Roberta R and 6 more authors..  (2016)  Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant..  Structure (London, England : 1993),  (4): [PMID:27618663]
13. Horita, Shoichiro S and 5 more authors..  (2016)  High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1..  Scientific reports,  (13): [PMID:27734966]
14. Tan, Shuguang S and 15 more authors..  (2017)  An unexpected N-terminal loop in PD-1 dominates binding by nivolumab..  Nature communications,  (6): [PMID:28165004]
15. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ..  (2018)  PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene..  Gene,  (5): [PMID:28951311]

溶液计算器